Clinical Trial Update: Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C

View source ↗

Summary

A prospective observational registry evaluating Infergen (interferon alfacon-1) for Hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Infergen (interferon alfacon-1)

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Hepatitis C | Status: WITHDRAWN